AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:07 2024-09-12 am EDT			5-day change	1st Jan Change
12,050.00 ^GBX	-2.10%		-3.91%	+13.68%

05:28pm	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT
08:50am	Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma	CI

ASTRAZENECA : Goldman Sachs gives a Buy rating

July 29, 2024 at 01:57 am EDT

Rajan Sharma from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price has been revised upwards and is now set at GBX 15756, compared with GBX 15131 previously.

Latest news about AstraZeneca PLC

European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	11:28am	MT
Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma	02:50am	CI
AlphaValue/Baader Europe Upgrades AstraZeneca to Add, Lifts PT	Sep. 11	MT
Nordea Bank Downgrades AstraZeneca to Sell	Sep. 11	MT
The mood is getting heavier, but Taylor Swift is keeping watch	Sep. 11
FTSE 100 in uninspiring gain before US data	Sep. 11	AN
ASTRAZENECA : Set to conquer new highs backed by ambitious goals	Sep. 11
AstraZeneca 'Working Very Closely' With Chinese Authorities on Probe, CEO Tells Bloomberg	Sep. 10	MT
European Equities Close Lower in Tuesday Trading; Apple, Google Lose Appeals Against European Commission	Sep. 10	MT
British Equities Retreat on Fresh UK Labor Market Data	Sep. 10	MT
European shares drop while BMW skids into reverse	Sep. 10	AN
Sophia Genetics Partners with AstraZeneca on Expanding Global Access to Liquid Biopsy Testing Option	Sep. 10	MT
ASTRAZENECA : Stifel confirms its recommendation on the stock	Sep. 10	CF
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing	Sep. 10	CI
ASTRAZENECA : disappointing test, Oddo BHF remains 'neutral	Sep. 10	CF
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	Sep. 10	ZD
Pascal Soriot, CEO of AstraZeneca : New lung cancer treatment shows two-month improvement in survival	Sep. 10	MT
Four steps back, one step forward	Sep. 10
ASTRAZENECA : UBS remains Sell on clinical trial results	Sep. 10	CF
Shares mixed as investors await US inflation	Sep. 10	AN
AstraZeneca Shares Slump After Cancer Drug Misses Key Target	Sep. 10	DJ
AstraZeneca share price falls, clinical trial unconvincing	Sep. 10	CF
AstraZeneca shares drop as lung cancer drug trial fails to improve survival	Sep. 10	RE
European stocks mixed before eyes turn stateside	Sep. 10	AN
FTSE 100 falls as AstraZeneca weighs; slowing wage growth cements rate cut bets	Sep. 10	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2024-09-11 - Analyst Meeting - Stifel

Related indices

STOXX Europe 600 Index (EUR) , FTSE 100

More about the company